10x Genomics, Inc. TXG Proceeds from exercises of stock options and other stock issuances
Proceeds from exercises of stock options and other stock issuances at other companies
Other financials
Where this comes from
Reported directly by 10x Genomics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.
The official record: 10x Genomics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about 10x Genomics, Inc.'s proceeds from exercises of stock options and other stock issuances.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 10x Genomics, Inc.'s proceeds from exercises of stock options and other stock issuances?
- 10x Genomics, Inc. (TXG) reported proceeds from exercises of stock options and other stock issuances of $273K in Q1 2026.
- How has 10x Genomics, Inc.'s proceeds from exercises of stock options and other stock issuances changed year-over-year?
- 10x Genomics, Inc.'s proceeds from exercises of stock options and other stock issuances decreased by 35.3% year-over-year, from $422K to $273K.
- What is the long-term trend for 10x Genomics, Inc.'s proceeds from exercises of stock options and other stock issuances?
- Over 4 years (2021 to 2025), 10x Genomics, Inc.'s proceeds from exercises of stock options and other stock issuances has grown at a -35.9% compound annual growth rate (CAGR), from $40.33M to $6.8M.